{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:34:52Z","timestamp":1789526092095,"version":"build-2803163510"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["2021JJ70133"],"award-info":[{"award-number":["2021JJ70133"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","award":["2021zzts1070"],"award-info":[{"award-number":["2021zzts1070"]}],"id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","award":["2022zzts0886"],"award-info":[{"award-number":["2022zzts0886"]}],"id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.cca.2022.09.022","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T21:35:55Z","timestamp":1664228155000},"page":"16-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Serum biomarkers for liver fibrosis"],"prefix":"10.1016","volume":"537","author":[{"given":"Zhiyang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2022.09.022_b0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2022.09.022_b0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","article-title":"Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues","volume":"65","author":"Parola","year":"2019","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.cca.2022.09.022_b0015","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2012.12.005","article-title":"The burden of liver disease in Europe: a review of available epidemiological data","volume":"58","author":"Blachier","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cca.2022.09.022_b0020","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.matbio.2018.04.006","article-title":"Liver fibrosis: Direct antifibrotic agents and targeted therapies","volume":"68\u201369","author":"Schuppan","year":"2018","journal-title":"Matrix Biol."},{"key":"10.1016\/j.cca.2022.09.022_b0025","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-022-00799-z","article-title":"Liver biopsy for assessment of chronic liver diseases: a synopsis","author":"Chowdhury","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.cca.2022.09.022_b0030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0140-6736(86)90883-4","article-title":"Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver","volume":"1","author":"Maharaj","year":"1986","journal-title":"Lancet."},{"key":"10.1016\/j.cca.2022.09.022_b0035","doi-asserted-by":"crossref","first-page":"11567","DOI":"10.3748\/wjg.v21.i41.11567","article-title":"Non-invasive diagnosis of liver fibrosis and cirrhosis","volume":"21","author":"Lurie","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cca.2022.09.022_b0040","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/gutjnl-2018-317593","article-title":"Advances in non-invasive assessment of hepatic fibrosis","volume":"69","author":"Loomba","year":"2020","journal-title":"Gut."},{"key":"10.1016\/j.cca.2022.09.022_b0045","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0009-8981(57)90027-X","article-title":"An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities","volume":"2","author":"De Ritis","year":"1957","journal-title":"Clin. Chim. Acta."},{"key":"10.1016\/j.cca.2022.09.022_b0050","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1572-0241.1998.044_c.x","article-title":"AST\/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection","volume":"93","author":"Sheth","year":"1998","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cca.2022.09.022_b0055","first-page":"734","article-title":"Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis","volume":"95","author":"Williams","year":"1988","journal-title":"Relationship to cirrhosis, Gastroenterol."},{"key":"10.1016\/j.cca.2022.09.022_b0060","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1572-0241.1999.01006.x","article-title":"The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease","volume":"94","author":"Sorbi","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cca.2022.09.022_b0065","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/alcalc\/agh074","article-title":"High AST\/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking","volume":"39","author":"Nyblom","year":"2004","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.cca.2022.09.022_b0070","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1478-3231.2006.01304.x","article-title":"The AST\/ALT ratio as an indicator of cirrhosis in patients with PBC","volume":"26","author":"Nyblom","year":"2006","journal-title":"Liver Int."},{"key":"10.1016\/j.cca.2022.09.022_b0075","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology."},{"key":"10.1016\/j.cca.2022.09.022_b0080","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/00365521.2020.1786599","article-title":"Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography","volume":"55","author":"Forsgren","year":"2020","journal-title":"Scand J. Gastroenterol."},{"key":"10.1016\/j.cca.2022.09.022_b0085","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/hep.27382","article-title":"Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis","volume":"61","author":"Xiao","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cca.2022.09.022_b0090","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"APRICOT Clinical Investigators, Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cca.2022.09.022_b0095","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut."},{"key":"10.1016\/j.cca.2022.09.022_b0100","series-title":"Care and Treatment of Persons with Hepatitis C Infection","author":"Guidelines for the Screening","year":"2014"},{"key":"10.1016\/j.cca.2022.09.022_b0105","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/gut.2007.146019","article-title":"Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease","volume":"57","author":"Harrison","year":"2008","journal-title":"Gut."},{"key":"10.1016\/j.cca.2022.09.022_b0110","doi-asserted-by":"crossref","first-page":"191","DOI":"10.23736\/S0026-4806.19.05978-0","article-title":"Older age and HDL-cholesterol as independent predictors of liver fibrosis assessed by BARD score","volume":"110","author":"Klisic","year":"2019","journal-title":"Minerva Med."},{"key":"10.1016\/j.cca.2022.09.022_b0115","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jhep.2010.06.028","article-title":"Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease","volume":"54","author":"Ruffillo","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cca.2022.09.022_b0120","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/hepr.12647","article-title":"Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study","volume":"46","author":"Sun","year":"2016","journal-title":"Hepatol Res."},{"key":"10.1016\/j.cca.2022.09.022_b0125","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO), EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, J Hepatol. 64 (2016) 1388\u20131402. 10.1016\/j.jhep.2015.11.004.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"10.1016\/j.cca.2022.09.022_b0130","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology."},{"key":"10.1016\/j.cca.2022.09.022_b0135","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cca.2022.09.022_b0140","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/j.gastro.2013.06.057","article-title":"Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"145","author":"Angulo","year":"2013","journal-title":"Gastroenterology."},{"key":"10.1016\/j.cca.2022.09.022_b0145","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.cca.2022.09.022_b0150","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.metabol.2016.01.013","article-title":"Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease: are We There Yet?","volume":"65","author":"Alkhouri","year":"2016","journal-title":"Metabolism."},{"key":"10.1016\/j.cca.2022.09.022_b0155","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1136\/gutjnl-2015-309260","article-title":"The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa","volume":"65","author":"Lemoine","year":"2016","journal-title":"Gut."},{"key":"10.1016\/j.cca.2022.09.022_b0160","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/liv.13688","article-title":"Validation and comparison of seventeen noninvasive models for evaluating liver fibrosis in Chinese hepatitis B patients","volume":"38","author":"Dong","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.cca.2022.09.022_b0165","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/gutjnl-2016-312658","article-title":"The \u03b3-glutamyl transpeptidase to platelet ratio (GPR) in HBV patients: just adding up?","volume":"66","author":"Schiavon","year":"2017","journal-title":"Gut."},{"key":"10.1016\/j.cca.2022.09.022_b0170","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0140-6736(00)04258-6","article-title":"MULTIVIRC Group, Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study","volume":"357","author":"Imbert-Bismut","year":"2001","journal-title":"Lancet."},{"key":"10.1016\/j.cca.2022.09.022_b0175","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/ajg.2014.21","article-title":"FibroTest\/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis","volume":"109","author":"Salkic","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cca.2022.09.022_b0180","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep.22576","article-title":"Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease","volume":"49","author":"Naveau","year":"2009","journal-title":"Hepatology."},{"key":"10.1016\/j.cca.2022.09.022_b0185","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/apt.13770","article-title":"FLIP Consortium and the FibroFrance Group, Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference","volume":"44","author":"Munteanu","year":"2016","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.cca.2022.09.022_b0190","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.22085","article-title":"The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases","volume":"47","author":"Adler","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cca.2022.09.022_b0195","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/apt.14990","article-title":"FibroFrance Group, Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease","volume":"48","author":"Munteanu","year":"2018","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.cca.2022.09.022_b0200","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.3390\/jcm10112415","article-title":"null On Behalf Of The Litmus Systematic Review Team, FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: a systematic review and meta-analysis,","volume":"10","author":"Vali","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cca.2022.09.022_b0205","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/hep.20935","article-title":"A novel panel of blood markers to assess the degree of liver fibrosis","volume":"42","author":"Cal\u00e8s","year":"2005","journal-title":"Hepatology."},{"key":"10.1016\/j.cca.2022.09.022_b0210","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0399-8320(08)73992-7","article-title":"FibroMeters: a family of blood tests for liver fibrosis","volume":"32","author":"Cal\u00e8s","year":"2008","journal-title":"Gastroenterol Clin Biol."},{"key":"10.1016\/j.cca.2022.09.022_b0215","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MEG.0b013e32830cebd7","article-title":"Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C","volume":"21","author":"Boursier","year":"2009","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cca.2022.09.022_b0220","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.clinbiochem.2008.06.020","article-title":"Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data","volume":"41","author":"Leroy","year":"2008","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.cca.2022.09.022_b0225","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/liv.12327","article-title":"ANRS HC EP 23 Fibrostar Study, Improved fibrosis staging by elastometry and blood test in chronic hepatitis C","volume":"34","author":"Cal\u00e8s","year":"2014","journal-title":"Liver Int."},{"key":"10.1016\/j.cca.2022.09.022_b0230","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jhep.2019.04.020","article-title":"New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD","volume":"71","author":"Boursier","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cca.2022.09.022_b0235","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1515\/CCLM.2011.640","article-title":"Golgi protein 73(GP73), a useful serum marker in liver diseases","volume":"49","author":"Liu","year":"2011","journal-title":"Clin. Chem. Lab Med."},{"key":"10.1016\/j.cca.2022.09.022_b0240","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s12016-017-8655-y","article-title":"The Clinical Significance of GP73 in immunologically mediated chronic liver diseases: experimental data and literature review","volume":"54","author":"Yao","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.cca.2022.09.022_b0245","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.3748\/wjg.v26.i34.5130","article-title":"Golgi protein-73: a biomarker for assessing cirrhosis and prognosis of liver disease patients","volume":"26","author":"Gatselis","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cca.2022.09.022_b0250","first-page":"361","article-title":"Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers, Expert Rev","volume":"13","author":"Agbim","year":"2019","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.cca.2022.09.022_b0255","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/ar.23567","article-title":"Basement Membrane Type IV Collagen and Laminin: an overview of their biology and value as fibrosis biomarkers of liver disease","volume":"300","author":"Mak","year":"2017","journal-title":"Anat. Rec. (Hoboken)."},{"key":"10.1016\/j.cca.2022.09.022_b0260","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/j.1530-0277.2008.00664.x","article-title":"Veterans Affairs Cooperative Study 391 Group, Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease","volume":"32","author":"Lieber","year":"2008","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.cca.2022.09.022_b0265","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/clinchem\/42.4.558","article-title":"Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis","volume":"42","author":"Gu\u00e9chot","year":"1996","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2022.09.022_b0270","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3748\/wjg.v8.i6.1073","article-title":"ROC curves in evaluation of serum fibrosis indices for hepatic fibrosis","volume":"8","author":"Zheng","year":"2002","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cca.2022.09.022_b0275","doi-asserted-by":"crossref","unstructured":"K.A. Gebo, H.F. Herlong, M.S. Torbenson, M.W. Jenckes, G. Chander, K.G. Ghanem, S.S. El-Kamary, M. Sulkowski, E.B. Bass, Role of liver biopsy in management of chronic hepatitis C: a systematic review, Hepatology. 36 (2002) S161-172. 10.1053\/jhep.2002.36989.","DOI":"10.1053\/jhep.2002.36989"},{"key":"10.1016\/j.cca.2022.09.022_b0280","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0168-8278(96)80239-X","article-title":"Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value","volume":"25","author":"K\u00f6rner","year":"1996","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cca.2022.09.022_b0285","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/0004563217707979","article-title":"Diagnostic accuracy of the Coopscore\u00a9 to predict liver fibrosis in human immunodeficiency virus\/hepatitis B virus co-infection","volume":"55","author":"Taibi","year":"2018","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.cca.2022.09.022_b0290","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cca.2012.09.020","article-title":"ANRS HCEP 23 Fibrostar Group, Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy","volume":"415","author":"Bosselut","year":"2013","journal-title":"Clin. Chim. Acta."},{"key":"10.1016\/j.cca.2022.09.022_b0295","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.26030","article-title":"Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease","volume":"57","author":"Tanwar","year":"2013","journal-title":"Hepatology."},{"key":"10.1016\/j.cca.2022.09.022_b0300","doi-asserted-by":"crossref","unstructured":"J.W, Day, W.M. Rosenberg, The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis, Br J Hosp Med (Lond). 79 (2018) 694\u2013699. 10.12968\/hmed.2018.79.12.694.","DOI":"10.12968\/hmed.2018.79.12.694"},{"key":"10.1016\/j.cca.2022.09.022_b0305","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/hep.30163","article-title":"An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis","volume":"69","author":"Daniels","year":"2019","journal-title":"Hepatology."},{"key":"10.1016\/j.cca.2022.09.022_b0310","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1053\/j.gastro.2018.01.005","article-title":"Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease","volume":"154","author":"Thiele","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cca.2022.09.022_b0315","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.matbio.2015.01.004","article-title":"Matrix metalloproteinases in liver injury, repair and fibrosis","volume":"44\u201346","author":"Duarte","year":"2015","journal-title":"Matrix Biol."},{"key":"10.1016\/j.cca.2022.09.022_b0320","first-page":"143","article-title":"Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review)","volume":"24","author":"Consolo","year":"2009","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.cca.2022.09.022_b0325","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S0168-8278(00)80230-5","article-title":"Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C","volume":"32","author":"Mitsuda","year":"2000","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cca.2022.09.022_b0330","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/hep4.1589","article-title":"Serum Matrix Metalloproteinase 7 Is a Diagnostic Biomarker of Biliary Injury and Fibrosis in Pediatric Autoimmune Liver Disease","volume":"4","author":"Lam","year":"2020","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.cca.2022.09.022_b0335","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41598-021-82315-z","article-title":"Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease","volume":"11","author":"Irvine","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2022.09.022_b0340","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.dld.2020.05.004","article-title":"Liver fibrosis improvement in chronic hepatitis C after direct acting-antivirals is accompanied by reduced profibrogenic biomarkers-a role for MMP-9\/TIMP-1","volume":"52","author":"Medeiros","year":"2020","journal-title":"Dig Liver Dis."},{"key":"10.1016\/j.cca.2022.09.022_b0345","doi-asserted-by":"crossref","first-page":"e92772","DOI":"10.1371\/journal.pone.0092772","article-title":"The performance of enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: a meta-analysis","volume":"9","author":"Xie","year":"2014","journal-title":"PLoS One."},{"key":"10.1016\/j.cca.2022.09.022_b0350","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/cid\/ciaa646","article-title":"The Enhanced Liver Fibrosis Index Predicts Hepatic Fibrosis Superior to FIB4 and APRI in HIV\/HCV Infected Patients","volume":"73","author":"Abdel-Hameed","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cca.2022.09.022_b0355","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2013.03.016","article-title":"The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values","volume":"59","author":"Lichtinghagen","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cca.2022.09.022_b0360","first-page":"254","article-title":"European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis","volume":"58","author":"Abignano","year":"2019","journal-title":"Rheumatol. (Oxford)."},{"key":"10.1016\/j.cca.2022.09.022_b0365","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jhep.2014.02.029","article-title":"Prospective evaluation of FibroTest\u00ae, FibroMeter\u00ae, and HepaScore\u00ae for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C","volume":"61","author":"Leroy","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cca.2022.09.022_b0370","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/liv.13116","article-title":"The ability of Hepascore to predict liver fibrosis in chronic liver disease: a meta-analysis","volume":"37","author":"Huang","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.cca.2022.09.022_b0375","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1515\/cclm-2012-0584","article-title":"High biological variation of serum hyaluronic acid and Hepascore, a biochemical marker model for the prediction of liver fibrosis","volume":"51","author":"Rossi","year":"2013","journal-title":"Clin. Chem. Lab Med."},{"key":"10.1016\/j.cca.2022.09.022_b0380","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1515\/cclm-2018-0357","article-title":"Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review","volume":"57","author":"Haghgoo","year":"2019","journal-title":"Clin. Chem. Lab Med."},{"key":"10.1016\/j.cca.2022.09.022_b0385","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1479-5876-6-72","article-title":"Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign?","volume":"6","author":"Tarantino","year":"2008","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cca.2022.09.022_b0390","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cytogfr.2015.10.002","article-title":"The PDGF system and its antagonists in liver fibrosis","volume":"28","author":"Borkham-Kamphorst","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cca.2022.09.022_b0395","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3748\/wjg.v9.i11.2490","article-title":"Diagnostic value of platelet derived growth factor-BB, transforming growth factor-\u03b21, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis","volume":"9","author":"Zhang","year":"2003","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cca.2022.09.022_b0400","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijid.2016.06.004","article-title":"China HepB-Related Fibrosis Assessment Research Group, Serum platelet-derived growth factor BB levels: a potential biomarker for the assessment of liver fibrosis in patients with chronic hepatitis B","volume":"49","author":"Zhou","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.cca.2022.09.022_b0405","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.matbio.2018.03.007","article-title":"Connective tissue growth factor (CTGF) from basics to clinics","volume":"68\u201369","author":"Ramazani","year":"2018","journal-title":"Matrix Biol."},{"key":"10.1016\/j.cca.2022.09.022_b0410","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cca.2013.02.029","article-title":"Connective tissue growth factor (CTGF\/CCN2) in serum is an indicator of fibrogenic progression and malignant transformation in patients with chronic hepatitis B infection","volume":"421","author":"Gressner","year":"2013","journal-title":"Clinica. Chimica. Acta."},{"key":"10.1016\/j.cca.2022.09.022_b0415","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.3748\/wjg.v18.i18.2280","article-title":"Clinical significance of connective tissue growth factor in hepatitis B virus-induced hepatic fibrosis","volume":"18","author":"Piao","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cca.2022.09.022_b0420","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1365-2893.2009.01110.x","article-title":"Validation of connective tissue growth factor (CTGF\/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis","volume":"16","author":"Kovalenko","year":"2009","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.cca.2022.09.022_b0425","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1373\/clinchem.2006.070466","article-title":"Connective Tissue Growth Factor in Serum as a New Candidate Test for Assessment of Hepatic Fibrosis","volume":"52","author":"Gressner","year":"2006","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2022.09.022_b0430","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/vim.2009.0067","article-title":"The level of connective tissue growth factor in sera of patients with hepatitis B virus strongly correlates with stage of hepatic fibrosis","volume":"23","author":"Guo-Qiu","year":"2010","journal-title":"Viral Immunol."},{"key":"10.1016\/j.cca.2022.09.022_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110680","article-title":"CHI3L1 in the pathophysiology and diagnosis of liver diseases","volume":"131","author":"Wang","year":"2020","journal-title":"Biomedicine & Pharmacotherapy."},{"key":"10.1016\/j.cca.2022.09.022_b0440","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1089\/omi.2015.0037","article-title":"CHI3L1 Is a Liver-Enriched, Noninvasive Biomarker That Can Be Used to Stage and Diagnose Substantial Hepatic Fibrosis","volume":"19","author":"Huang","year":"2015","journal-title":"OMICS."},{"key":"10.1016\/j.cca.2022.09.022_b0445","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s15010-018-1136-2","article-title":"China HepB-Related Fibrosis Assessment Research Group, Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT","volume":"46","author":"Yan","year":"2018","journal-title":"Infection."},{"key":"10.1016\/j.cca.2022.09.022_b0450","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3748\/wjg.v11.i4.476","article-title":"Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease","volume":"11","author":"Saitou","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cca.2022.09.022_b0455","doi-asserted-by":"crossref","first-page":"3227957","DOI":"10.1155\/2022\/3227957","article-title":"Diagnostic Value of Serum Chitinase-3-Like Protein 1 for Liver Fibrosis: a Meta-analysis","volume":"2022","author":"Huang","year":"2022","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.cca.2022.09.022_b0460","doi-asserted-by":"crossref","unstructured":"N. Nishimura, D. De Battista, D.R. McGivern, R.E. Engle, A. Tice, R. Fares-Gusmao, J. Kabat, A. Pomerenke, H. Nguyen, S. Sato, K.W. Bock, I.N. Moore, D.E. Kleiner, F. Zamboni, H.J. Alter, S. Govindarajan, P. Farci, Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis, Proc Natl Acad Sci U S A. 118 (2021) e2019633118. 10.1073\/pnas.2019633118.","DOI":"10.1073\/pnas.2019633118"},{"key":"10.1016\/j.cca.2022.09.022_b0465","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3892\/etm.2020.8798","article-title":"Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B","volume":"20","author":"Tsuji","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.cca.2022.09.022_b0470","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41424-018-0020-9","article-title":"Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection","volume":"9","author":"Mak","year":"2018","journal-title":"Clin. Transl Gastroenterol."},{"key":"10.1016\/j.cca.2022.09.022_b0475","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.3748\/wjg.v26.i21.2864","article-title":"M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals","volume":"26","author":"Saleh","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cca.2022.09.022_b0480","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00535-014-1007-2","article-title":"Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease","volume":"50","author":"Abe","year":"2015","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.cca.2022.09.022_b0485","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/hepr.13608","article-title":"Mac-2 binding protein glycan isomer as noninvasive tool to assess liver fibrosis in children with chronic liver disease","volume":"51","author":"Behairy","year":"2021","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.cca.2022.09.022_b0490","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00535-017-1425-z","article-title":"Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis","volume":"53","author":"Shirabe","year":"2018","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.cca.2022.09.022_b0495","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3727\/105221615X14399878166078","article-title":"Role of Noncoding RNAs as Biomarker and Therapeutic Targets for Liver Fibrosis","volume":"16","author":"Teng","year":"2015","journal-title":"Gene Expr."},{"key":"10.1016\/j.cca.2022.09.022_b0500","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hep.32239","article-title":"Liver fibrosis: extracellular vesicles mediated intercellular communication in perisinusoidal space","volume":"76","author":"Devaraj","year":"2022","journal-title":"Hepatology."},{"key":"10.1016\/j.cca.2022.09.022_b0505","doi-asserted-by":"crossref","first-page":"8139","DOI":"10.3390\/ijms22158139","article-title":"Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA","volume":"22","author":"Tadokoro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2022.09.022_b0510","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jhep.2014.07.017","article-title":"Circulating microRNAs as markers of liver inflammation, fibrosis and cancer","volume":"61","author":"Roderburg","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cca.2022.09.022_b0515","doi-asserted-by":"crossref","first-page":"E1767","DOI":"10.3390\/cells9081767","article-title":"MicroRNA-221: a fine tuner and potential biomarker of chronic liver injury","volume":"9","author":"Markovic","year":"2020","journal-title":"Cells."},{"key":"10.1016\/j.cca.2022.09.022_b0520","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s12072-021-10277-5","article-title":"miR-98-5p as a novel biomarker suppress liver fibrosis by targeting TGF\u03b2 receptor 1","volume":"16","author":"Ma","year":"2022","journal-title":"Hepatol Int."},{"key":"10.1016\/j.cca.2022.09.022_b0525","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/apt.16177","article-title":"Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study","volume":"53","author":"Zhang","year":"2021","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.cca.2022.09.022_b0530","article-title":"LITMUS Consortium Investigators\u00a7, LITMUS Consortium Investigators, Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance","volume":"4","author":"Johnson","year":"2022","journal-title":"JHEP Rep."},{"key":"10.1016\/j.cca.2022.09.022_b0535","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/1751-2980.12452","article-title":"MicroRNA profile analysis in the liver fibrotic tissues of chronic hepatitis B patients","volume":"18","author":"Chen","year":"2017","journal-title":"J. Dig. Dis."},{"key":"10.1016\/j.cca.2022.09.022_b0540","doi-asserted-by":"crossref","first-page":"860","DOI":"10.5009\/gnl16560","article-title":"Serum MicroRNA Levels as a Noninvasive Diagnostic Biomarker for the Early Diagnosis of Hepatitis B Virus-Related Liver Fibrosis","volume":"11","author":"Bao","year":"2017","journal-title":"Gut. Liver."},{"key":"10.1016\/j.cca.2022.09.022_b0545","doi-asserted-by":"crossref","first-page":"e32999","DOI":"10.1371\/journal.pone.0032999","article-title":"Micro-RNA Profiling in Human Serum Reveals Compartment-Specific Roles of miR-571 and miR-652 in Liver Cirrhosis","volume":"7","author":"Roderburg","year":"2012","journal-title":"PLoS One."},{"key":"10.1016\/j.cca.2022.09.022_b0550","first-page":"970","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study, Lancet","volume":"5","author":"Harrison","year":"2020","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.cca.2022.09.022_b0555","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cmet.2019.07.011","article-title":"Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease","volume":"30","author":"Mori","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.cca.2022.09.022_b0560","first-page":"147","article-title":"Using Next-generation Sequencing to Identify Novel Exosomal miRNAs as Biomarkers for Significant Hepatic Fibrosis","volume":"31","author":"Wang","year":"2021","journal-title":"Discov Med."},{"key":"10.1016\/j.cca.2022.09.022_b0565","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1038\/emm.2015.68","article-title":"Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma","volume":"47","author":"Sohn","year":"2015","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.cca.2022.09.022_b0570","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/liv.14167","article-title":"Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity","volume":"39","author":"Di Mauro","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.cca.2022.09.022_b0575","unstructured":"M.-J. Chen, X.-G. Wang, Z.-X. Sun, X.-C. Liu, Diagnostic value of LncRNA-MEG3 as a serum biomarker in patients with hepatitis B complicated with liver fibrosis, Eur Rev Med Pharmacol Sci. 23 (2019) 4360\u20134367. 10.26355\/eurrev_201905_17943."},{"key":"10.1016\/j.cca.2022.09.022_b0580","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/jvh.12680","article-title":"Serum lincRNA-p21 as a potential biomarker of liver fibrosis in chronic hepatitis B patients","volume":"24","author":"Yu","year":"2017","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.cca.2022.09.022_b0585","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.7150\/thno.32935","article-title":"SCARNA10, a nuclear-retained long non-coding RNA, promotes liver fibrosis and serves as a potential biomarker","volume":"9","author":"Zhang","year":"2019","journal-title":"Theranostics."},{"key":"10.1016\/j.cca.2022.09.022_b0590","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/hep.30698","article-title":"Long Noncoding RNA H19 Contributes to Cholangiocyte Proliferation and Cholestatic Liver Fibrosis in Biliary Atresia","volume":"70","author":"Xiao","year":"2019","journal-title":"Hepatology."},{"key":"10.1016\/j.cca.2022.09.022_b0595","article-title":"Long Noncoding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 in Extracellular Vesicles Promotes Hepatic Stellate Cell Activation","volume":"13","author":"Wang","year":"2022","journal-title":"Liver Fibrosis and \u03b2-Catenin Signaling Pathway, Front Physiol."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898122013201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898122013201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:05:24Z","timestamp":1757862324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898122013201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":119,"alternative-id":["S0009898122013201"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2022.09.022","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum biomarkers for liver fibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2022.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}